SAN DIEGO, June 12, 2009 (GLOBE NEWSWIRE) -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that its TearLab(tm) Osmolarity System has received a Silver 2009 Medical Design Excellence Award (MDEA).
The winning products in this year's Medical Design Excellence Awards (MDEA) competition, sponsored by Canon Communications, received their gold or silver recognition at a ceremony held yesterday during the Medical Design & Manufacturing East (MD&M East) 2009 Conference and Exposition at the Jacob K. Javits Convention Center in New York City.
MDEA is the premier awards program for the medical technology community. It recognizes the achievements of medical device manufacturers, their suppliers, and the many people behind the scenes-engineers, scientists, designers, and clinicians-who are responsible for the groundbreaking innovations that are changing the face of healthcare. MDEA-winning entries excel in the areas of product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery.
"We are thrilled with our Silver MDEA award," said Eric Donsky, CEO TearLab Corporation. "Our recent FDA clearance and the announcement of our Silver award further validates the breakthrough in technology delivered in the TearLab Osmolarity System. In the development of this innovative, point-of-care diagnostic product, our engineering team, led by Dr. Benjamin Sullivan and Steve Zmina, along with our dedicated partners, Minifab & Invetech, worked tirelessly to overcome the many challenges of establishing a product capable of precisely measuring a diagnostic marker in 50 nanoliters of tears within seconds while maintaining a simple user interface for a technician to achieve repeatable results in an office setting. We thank the judges for their appreciation of the huge potential of TearLab(tm) as a non-invasive diagnostic platform."
About OccuLogix, Inc. dba TearLab Corporation
OccuLogix dba TearLab Corporation (www.tearlab.com) is an ophthalmic device company developing and commercializing novel, lab-on-a-chip technologies (integrating one or several laboratory functions on a chip only millimeters in size) that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.
Forward-Looking Statements
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.